# Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)

Study · id `cardio:ct-nct03603912` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03603912](<https://clinicaltrials.gov/study/NCT03603912>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03603912

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.

## Technical summary

Registry record NCT03603912. Randomized; single masking; primary purpose treatment. Start 2018-08-24 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT03603912, source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)
- Started: 2018-08-24 (actual) (ClinicalTrials.gov record NCT03603912, source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03603912, source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT03603912, source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03603912, source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03603912-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
- Acronym: TRIM-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Metformin
- Intervention (Behavioral): Lifestyle/Risk Factor Modification
- Lead sponsor: Mina Chung, MD
- Lead sponsor class: OTHER
- Collaborator: American Heart Association
- Collaborator class: OTHER
- Collaborator: The Cleveland Clinic
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: American Heart Association (`core:aha`)
- Registry lists this organization as a collaborator: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)

## Provenance

Content hash: 559f127b231480a14a7b49edae30461e82412fc7ee417d7401c69228942ab3e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
